Market capitalization | $50.16m |
Enterprise Value | $42.93m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 53.66 |
P/S ratio (TTM) P/S ratio | 62.70 |
P/B ratio (TTM) P/B ratio | negative |
Sales growth (TTM) Sales growth | 133.06% |
Turnover (TTM) Turnover | $800.00k |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
4 Analysts have issued a VolitionRX forecast:
4 Analysts have issued a VolitionRX forecast:
Mar '24 |
+/-
%
|
||
Turnover | 0.80 0.80 |
135%
135%
|
|
Gross income | -0.60 -0.60 |
-
|
|
EBITDA | -34 -34 |
6%
6%
|
EBIT (operating result) EBIT | -35 -35 |
7%
7%
|
Net profit | -35 -35 |
11%
11%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
Head office | United States |
CEO | Cameron Reynolds |
Employees | 110 |
Founded | 1998 |
Website | www.volition.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.